Though not the main conclusion, this article suggests that dasatanib may be an even better therapy than gleevec for CML patients because dasatanib also inhibits Src signaling in addition to Bcr-Abl.
If so, from a business perspective, BMS just became a bit more valuable. Analysts predict annual sales of $500M for dasatanib (Sprycel), but it if this article is right, may be more like Gleevec's $2.2B annual revenue.
Does this suggest a Novartis buy-out of BMS?
BMS is trading at $24.50.
Monday, November 13, 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment